DEFAR - Artigos publicados em periódicos
URI permanente para esta coleçãohttp://www.hml.repositorio.ufop.br/handle/123456789/531
Navegar
3 resultados
Resultados da Pesquisa
Item Public programs for essential medicine access in a small municipality : a cross-sectional analysis.(2022) Chaves, Zeó Jaime Lacerda; Silva, Luiz Sérgio; Nascimento, Renata Cristina Rezende Macedo doBackground: Public programs that provide access to essential medications have played an important role in the care of hypertensive and diabetic patients. However, access in small municipalities has been poorly studied. Objective: To describe the sociodemographic profile and the medication and health service usage of patients with systemic arterial hypertension and/or diabetes mellitus in a small municipality who use the public medication access programs Health has no Price (Saúde Não Tem Preço - SNTP) and the Minas Pharmacy Network. Methods: This cross-sectional study with 341 participants was conducted in 2019. Home interviews were conducted using a standardized, semi-structured questionnaire. The data are expressed as absolute and relative frequencies, and Pearson's chi-square test was used for comparisons between proportions (α = 5%). Results: Most of the participants (70.68%) had hypertension only, 11.14% had diabetes only, and 18.18% had both. Regarding the origin of the hypertension medications, 82.67% were provided by the Minas Pharmacy Network and/or SNTP programs. Regarding oral hypoglycemic agents and insulins, 88.61% were provided by the Minas Pharmacy Network and/or SNTP. Most participants were female (63.1%), at least 65 years of age (50.30%), non- White (66.96%), resided in an urban area (67.16%), were illiterate or had a low education level (89.94%), and had a maximum income ≤ 2 times the federal minimum salary (89.19%). Overall user perception was significantly better for SNTP (p=0.010). Conclusion: The results of this study indicate that programs which provide access to essential medications are important sources of hypertension and diabetes medications in the study area, especially for people with low incomes.Item A new Brazilian regional scenario of Type 2 diabetes risk in the next ten years.(2021) Nascimento, Lúbia Guaima; Nascimento, Renata Cristina Rezende Macedo do; Frade, Josélia Cintya Quintão Pena; Pinheiro, Eliete Bachrany; Ferreira, Wesley Magno; Reis, Janice Sepúlveda; Melo, Karla Fabiana Santana de; Pontarolo, Roberto; Lenzi, Mônica Soares Amaral; Almeida, José Vanilton de; João, Walter Jorge; Pedrosa, Hermelinda Cordeiro; Correr, Cassyano Januário; Vital, Wendel CouraAims: According to a recent national diabetes screening performed by our group in 2018, 18.4% of the Brazilians were found to have high blood glucose. The objective of the present study was to estimate the risk of developing type 2 DM (T2DM) in the next ten years in Brazilian population. Methods: A cross-sectional study was carried out in community pharmacies across Brazil, in 2018, where pharmacists applied the FINDRISC questionnaire to estimate the population’s risk of developing T2DM within a ten-year period. Results: The study included 977 pharmacists from 345 municipalities distributed across the five geograph- ical regions of Brazil. Of the 17,580 people evaluated, the South region was found to have the highest frequency (59.6%) among people at very low and/or low risk of developing T2DM, while the North region, the most underserved, presented the highest and/or very highest T2DM risk (24.1%). The factors that mostly and importantly impacted these regional differences were body mass index; the highest daily consumption of vegetables and fruits; history of high blood glucose and family history of T1DM/T2DM. Conclusion: These results showed an impressive change of direction concerning diabetes numbers between the most underserved region in public health care and one of the most developed and best organized regions concerning health assistance, the North and the South, respectively.Item Pharmaceutical care program for type 2 diabetes patients in Brazil : a randomised controlled trial.(2012) Mourão, Aline de Oliveira Magalhães; Ferreira, Wandiclécia Rodrigues; Martins, Maria Auxiliadora Parreiras; Reis, Adriano Max Moreira; Carrilo, Maria Ruth Gaede Gonçalves; Guimarães, Andrea Grabe; Ev, Lisiane da SilveiraBackground Brazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73 % of them have poor glycaemic control. Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients. Objective To evaluate the effect of a pharmaceutical care program on blood glucose, blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes. Setting Six primary care units of the Brazilian public health system, Ouro Preto, Brazil. Method An open, randomised, controlled clinical trialwas conducted for 6 months. Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels C7 % were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention. Main outcome measure Haemoglobin A1C. Results A total of 129 subjects were enrolled, and 100 patients completed the study. Compared to the control group (n = 50), the intervention group (n = 50) showed a significant reduction of haemoglobin A1C (-0.6 vs 0.7 %, p = 0.001), fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipid-modifying agents and platelet aggregation inhibitors. Conclusions This study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients. Moreover, the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil.